Shorter TB treatment for children
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is under 10 years old and weighs at least 3 kg (about 6.6 pounds).
- Your child has been diagnosed with tuberculosis (TB) of the lungs or lymph nodes, and the doctor plans to use standard TB medications.
- Blood test results must be within certain safe ranges (liver, kidney, and blood cell counts).
- If your child has HIV, they must be on or able to start a specific HIV medication (dolutegravir).
- Girls who have started their period must have a negative pregnancy test and agree to use non-hormonal birth control if needed.
- Your child has not been treated for TB for more than 10 days recently, and does not have drug-resistant TB.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a shorter course of tuberculosis (TB) medicine works as well as the current longer treatment for children. If successful, it means fewer days of medicine and fewer side effects for kids.
This trial tests a shorter treatment regimen for people with tuberculosis (TB) who don't have symptoms. If you have TB bacteria in your lungs but no cough, fever, night sweats, or weight loss, this study may offer a more convenient treatment option.
This study tests a shorter treatment for a type of TB that is resistant to rifampicin (a common TB medicine) but still sensitive to isoniazid. It aims to see if this shorter regimen is as effective as the current longer one, potentially making treatment less burdensome for patients.
This study tests different treatment plans for people with tuberculosis (TB) that can be cured with standard medicines. It aims to find the best treatment for each person based on their risk score, which may lead to shorter or more effective treatment.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This trial tests whether a higher dose of the antibiotic rifampicin can shorten tuberculosis treatment from 6 months to 4 months. If you have drug-sensitive TB, this could mean fewer months of medication and fewer side effects.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.